| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
310.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2014-01-02 |
4 |
OE |
$0.38 |
$1,332 |
I/I |
3,505 |
83,721 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2013-12-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,000 |
80,216 |
|
- |
|
| Gibson Neil W |
Chief Scientific Officer |
• – – |
2013-02-04 |
4 |
OE |
$1.74 |
$87,000 |
D/D |
50,000 |
50,000 |
|
- |
|
| Astrazeneca Ab |
10% Owner |
– – • |
2012-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,250,000 |
|
- |
|
| Greene Barry E |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,150,500 |
6,150,500 |
|
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2012-10-10 |
4 |
B |
$4.00 |
$3,000,000 |
D/D |
750,000 |
7,049,500 |
2.45 |
- |
|
| Isis Pharmaceuticals Inc |
10% Owner |
– – • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
6,299,500 |
6,299,500 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
6,150,500 |
6,150,500 |
|
- |
|
| Maraganore John |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,150,500 |
6,150,500 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2012-10-10 |
4 |
B |
$4.00 |
$3,000,000 |
I/I |
750,000 |
7,049,500 |
2.25 |
- |
|
| Parshall B Lynne |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,299,500 |
6,299,500 |
|
- |
|
| Crooke Stanley T |
Director |
– • • |
2012-10-10 |
4 |
B |
$4.00 |
$3,000,000 |
I/I |
750,000 |
7,049,500 |
2.25 |
- |
|
| Crooke Stanley T |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,299,500 |
6,299,500 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2012-10-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,749,999 |
|
- |
|
| Menzel Garry E |
COO & Executive VP, FinanceOff |
• – – |
2012-10-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
111,842 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEOOfficer |
• • – |
2012-10-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
82,216 |
|
- |
|
341 Records found
|
|
Page 14 of 14 |
|
|
0.09 (4.16%) 
